Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.